Blue test tubes arranged in a line, disappearing into the background

Drug news

Kamada files MAA at EMA for inhaled alpha-1 antitrypsin (AAT) therapy.

Read time: 1 mins

Last updated:11th Apr 2016

Published:11th Apr 2016

Source: Pharmawand

Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, announced the submission of a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for the Company�s proprietary, inhaled alpha-1 antitrypsin (AAT) therapy as a treatment for AAT deficiency (AATD). The filing was validated by the EMA.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

News

BeiGene Licenses CSPC’s SYH2039 for Solid Tumor Treatment

BeiGene has entered into a global licensing agreement with CSPC for SYH2039, a novel MAT2A inhibitor targeting solid tumors with MTAP deletion, which is present in about 15% of all cancer types. Under the agreement, BeiGene will develop, manufacture, and commercialize SYH2039 worldwide, with CSPC receiving up to $150 million in upfront and milestone payments.

1 mins

News

Epkinly Shows Deep Responses in Relapsed CLL

Epkinly (epcoritamab-bysp) monotherapy has shown significant clinical activity, generating deep responses in heavily pretreated patients with relapsed/refractory chronic lymphocytic leukemia (CLL) according to the EPCORE CLL-1 trial. The trial results were presented at the 2024 ASH Annual Meeting & Exposition.

5 min

News

CHMP Backs Welireg for VHL Disease and RCC

The CHMP has given a positive opinion for Merck’s Welireg (belzutifan) to treat von Hippel-Lindau disease-associated tumors and advanced renal cell carcinoma. This recommendation is based on data from the LITESPARK-004 and LITESPARK-005 trials.

2 min

See all news